1 Real World Data, GlaxoSmithKline, Uxbridge, UK.
2 Worldwide Research and Development, Pfizer, Genome Sciences and Technologies, New York, USA.
3 Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands.
4 Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Barcelona, Spain.
5 Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
6 Quintile IMS, London, UK.
7 Health Search, Italian College of General Practitioners and Primary Care, Firenze, Italy.
8 Genetics, GlaxoSmithKline, Collegeville, PA, USA.
9 GlaxoSmithKline, Medicines Research Centre, Cambridge, UK.
10 University of Glasgow, Glasgow, UK.
11 Barts Liver Centre, Blizard Institute, Queen Mary, University of London, London, UK. firstname.lastname@example.org.
Non-alcoholic fatty liver disease (NAFLD) is a common condition that progresses in some patients to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Here we used healthcare records of 18 million adults to estimate risk of acquiring advanced liver disease diagnoses in patients with NAFLD or NASH compared to individually matched controls.
Data were extracted from four European primary care databases representing the UK, Netherlands, Italy and Spain. Patients with a recorded diagnosis of NAFLD or NASH (NAFLD/NASH) were followed up for incident cirrhosis and HCC diagnoses. Each coded NAFLD/NASH patient was matched to up to 100 "non-NAFLD" patients by practice site, gender, age ± 5 years and visit recorded within ± 6 months. Hazard ratios (HR) were estimated using Cox models adjusted for age and smoking status and pooled across databases by random effects meta-analyses.
Out of 18,782,281 adults, we identified 136,703 patients with coded NAFLD/NASH. Coded NAFLD/NASH patients were more likely to have diabetes, hypertension and obesity than matched controls. HR for cirrhosis in patients compared to controls was 4.73 (95% CI 2.43-9.19) and for HCC, 3.51 (95% CI 1.72-7.16). HR for either outcome was higher in patients with NASH and those with high-risk Fib-4 scores. The strongest independent predictor of a diagnosis of HCC or cirrhosis was baseline diagnosis of diabetes.
Real-world population data show that recorded diagnosis of NAFLD/NASH increases risk of life-threatening liveroutcomes. Diabetes is an independent predictor of advanced liver disease diagnosis, emphasising the need to identify specific groups of patients at highest risk.